In the last trading session, 2.84 million Esperion Therapeutics Inc. (NASDAQ:ESPR) shares changed hands as the company’s beta touched 0.99. With the company’s per share price at $2.04 changed hands at -$0.07 or -3.32% during last session, the market valuation stood at $400.29M. ESPR’s last price was a discount, traded about -66.67% off its 52-week high of $3.40. The share price had its 52-week low at $0.71, which suggests the last value was 65.2% up since then. When we look at Esperion Therapeutics Inc.’s average trading volume, we note the 10-day average is 2.98 million shares, with the 3-month average coming to 3.76 million.

Analysts gave the Esperion Therapeutics Inc. (ESPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ESPR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Esperion Therapeutics Inc.’s EPS for the current quarter is expected to be -0.16.

Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information

Instantly ESPR was in red as seen at the end of in last trading. With action 3.55%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -31.77%, with the 5-day performance at 3.55% in the green. However, in the 30-day time frame, Esperion Therapeutics Inc. (NASDAQ:ESPR) is 16.57% up. Looking at the short shares, we see there were 37.47 million shares sold at short interest cover period of 12.69 days.

The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 87.25% from its current market value. According to analyst projections, ESPR’s forecast low is 12 with 20 as the target high. To hit the forecast high, the stock’s price needs a -880.39% plunge from its current level, while the stock would need to soar -488.24% for it to hit the projected low.

Esperion Therapeutics Inc. (ESPR) estimates and forecasts

Data shows that the Esperion Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 4.62% over the past 6 months, a 98.03% in annual growth rate that is considerably higher than the industry average of 17.50%. Year-over-year growth is forecast to reach 199.10% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 53.52M. 5 analysts are of the opinion that Esperion Therapeutics Inc.’s revenue for the current quarter will be 62.42M. The estimates for the next quarter sales put growth at 93.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 23.09%. The 2024 estimates are for Esperion Therapeutics Inc. earnings to increase by 87.00%, but the outlook for the next 5-year period is at 16.90% per year.

ESPR Dividends

Esperion Therapeutics Inc. is expected to release its next quarterly earnings report in November.

Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.50% of Esperion Therapeutics Inc. shares while 68.74% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 69.08%. There are 68.74% institutions holding the Esperion Therapeutics Inc. stock share, with WASATCH ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 9.9628% of the shares, roughly 16.86 million ESPR shares worth $37.44 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.2617% or 13.98 million shares worth $31.04 million as of 2024-06-30.